Literature DB >> 24695082

Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.

Kendra H Oliver1, Tammy Jessen, Emily L Crawford, Chang Y Chung, James S Sutcliffe, Ana M Carneiro.   

Abstract

The plasma-membrane integrin αIIbβ3 (CD41/CD61, GPIIbIIIa) is a major functional receptor in platelets during clotting. A common isoform of integrin β3, Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial. To better understand the molecular mechanisms by which this sequence variation modifies platelet function, we produced transgenic knockin mice expressing a Pro32Pro33 integrin β3. Consistent with reports utilizing human platelets, we found significantly reduced bleeding and clotting times, as well as increased in vivo thrombosis, in Pro32Pro33 homozygous mice. These alterations paralleled increases in platelet attachment and spreading onto fibrinogen resulting from enhanced integrin αIIbβ3 function. Activation with protease-activated receptor 4- activating peptide, the main thrombin signaling receptor in mice, showed no significant difference in activation of Pro32Pro33 mice as compared with controls, suggesting that inside-out signaling remains intact. However, under unstimulated conditions, the Pro32Pro33 mutation led to elevated Src phosphorylation, facilitated by increased talin interactions with the β3 cytoplasmic domain, indicating that the αIIbβ3 intracellular domains are primed for activation while the ligand-binding domain remains unchanged. Acute dosing of animals with a Src inhibitor was sufficient to rescue the clotting phenotype in knockin mice to wild-type levels. Together, our data establish that the Pro32Pro33 structural alteration modifies the function of integrin αIIbβ3, priming the integrin for outside-in signaling, ultimately leading to hypercoagulability. Furthermore, our data may support a novel approach to antiplatelet therapy by Src inhibition where hemostasis is maintained while reducing risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24695082      PMCID: PMC4014669          DOI: 10.1124/mol.114.091736

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  62 in total

1.  A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit.

Authors:  O Vinogradova; T Haas; E F Plow; J Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  PlA2, a variant of GPIIIa implicated in coronary thromboembolic complications.

Authors:  P J Goldschmidt-Clermont; G E Cooke; G M Eaton; P F Binkley
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

3.  Evaluation of platelet function by flow cytometry.

Authors:  A D Michelson; M R Barnard; L A Krueger; A L Frelinger; M I Furman
Journal:  Methods       Date:  2000-07       Impact factor: 3.608

4.  Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury.

Authors:  A Undas; K Brummel; J Musial; K G Mann; A Szczeklik
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

5.  Involvement of Hic-5 in platelet activation: integrin alphaIIbbeta3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2.

Authors:  M Osada; T Ohmori; Y Yatomi; K Satoh; S Hosogaya; Y Ozaki
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

6.  C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality.

Authors:  J Fang; P Nurden; P North; A T Nurden; L M Du; N Valentin; D A Wilcox
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

7.  Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.

Authors:  D H Boschelli; Y D Wang; F Ye; B Wu; N Zhang; M Dutia; D W Powell; A Wissner; K Arndt; J M Weber; F Boschelli
Journal:  J Med Chem       Date:  2001-03-01       Impact factor: 7.446

8.  Variable protection of beta 3-integrin--deficient mice from thrombosis initiated by different mechanisms.

Authors:  S S Smyth; E D Reis; H Väänänen; W Zhang; B S Coller
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 9.  Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration.

Authors:  Tracee S Panetti
Journal:  Front Biosci       Date:  2002-01-01

10.  A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype.

Authors:  C Ruiz; C Y Liu; Q H Sun; M Sigaud-Fiks; E Fressinaud; J Y Muller; P Nurden; A T Nurden; P J Newman; N Valentin
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

View more
  4 in total

1.  The Gain-of-Function Integrin β3 Pro33 Variant Alters the Serotonin System in the Mouse Brain.

Authors:  Michael R Dohn; Christopher G Kooker; Lisa Bastarache; Tammy Jessen; Capria Rinaldi; Seth Varney; Matthew D Mazalouskas; Hope Pan; Kendra H Oliver; Digna R Velez Edwards; James S Sutcliffe; Joshua C Denny; Ana M D Carneiro
Journal:  J Neurosci       Date:  2017-10-16       Impact factor: 6.167

2.  Loss of Serotonin Transporter Function Alters ADP-mediated Glycoprotein αIIbβ3 Activation through Dysregulation of the 5-HT2A Receptor.

Authors:  Kendra H Oliver; Matthew T Duvernay; Heidi E Hamm; Ana M D Carneiro
Journal:  J Biol Chem       Date:  2016-07-15       Impact factor: 5.157

3.  Structure of an extended β3 integrin.

Authors:  Dongwen Zhou; Aye Myat Myat Thinn; Yan Zhao; Zhengli Wang; Jieqing Zhu
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

Review 4.  Protein ensembles link genotype to phenotype.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  PLoS Comput Biol       Date:  2019-06-20       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.